Key facts
- What it is: GHRP-2, also called pralmorelin, is a synthetic growth hormone-releasing peptide that activates the ghrelin or growth-hormone secretagogue receptor.
- Evidence: Human endocrine pharmacology, no established performance indication.
- Status: Not FDA-approved for bodybuilding or anti-aging.
- Main caution: Potential effects include appetite changes, fluid retention, glucose disruption, and changes in cortisol or prolactin.
- Sources: 5 PubMed-indexed papers linked below.
What is GHRP-2?
GHRP-2, also called pralmorelin, is a synthetic growth hormone-releasing peptide that activates the ghrelin or growth-hormone secretagogue receptor. Researchers have used it to probe pituitary function and GH physiology. Online bodybuilding use is a separate, unapproved practice unsupported by robust clinical outcome trials.
The first SEO trap with peptide content is treating every compound as if it belongs to the same category. It does not. Some peptides are approved prescription medicines supported by randomized trials; others are endogenous signaling molecules being studied in cells; others are unapproved chemicals sold with no regulated manufacturing chain. For GHRP-2, the evidence and regulatory category above determine what conclusions are reasonable.
This guide does not provide a dose, cycle, protocol, source, or personal recommendation. It translates published research so readers can distinguish a measured result from a marketing claim and bring better questions to a licensed clinician.
How does GHRP-2 work?
GHRP-2 stimulates pulsatile growth hormone release through GHSR signaling and can work synergistically with growth-hormone-releasing hormone. The receptor also participates in appetite and metabolic signaling, so the peptide is not a selective muscle-growth switch. Acute hormone release does not by itself prove durable changes in body composition or performance.
Mechanism is not the same as clinical benefit. A compound can activate a receptor, change a biomarker, or improve an animal model without improving how people feel, function, or survive. The strongest medical claims require controlled human outcomes, not a plausible pathway alone.
What does the research on GHRP-2 show?
Human studies demonstrate neuroendocrine activity, including GH release in experimental and critical-illness settings. Reviews describe diagnostic and pharmacologic research, while anti-doping literature confirms misuse. There is no comparable randomized clinical program showing that self-administered GHRP-2 safely improves strength, recovery, or healthy aging.
These papers were selected to show the shape of the evidence: foundational biology, clinical trials where they exist, safety signals, and reviews that place single studies in context. A citation does not mean PepMate endorses a treatment; it lets readers inspect the original record.
How strong is the evidence?
Evidence assessment: Human endocrine pharmacology, no established performance indication. Many papers measure hormone concentrations over hours rather than patient-centered outcomes over months. Critical-illness and diagnostic studies do not establish benefits for healthy athletes.
Evidence strength depends on study design, directness, replication, sample size, and whether researchers measured a meaningful outcome. Animal evidence can justify a human trial, but it cannot establish a human treatment. Observational human data can identify associations, but it cannot reliably prove cause and effect.
Is GHRP-2 approved or available?
Not FDA-approved for bodybuilding or anti-aging. Approval is tied to a specific product, indication, population, formulation, and regulator. “Research use only,” clinic availability, compounding, or a listing on a peptide website is not the same as approval. Availability can change, so current regulator labeling and professional guidance take priority over any static article.
GHRP-2 safety, risks, and evidence gaps
Potential effects include appetite changes, fluid retention, glucose disruption, and changes in cortisol or prolactin. Product purity is an additional risk when material comes from unregulated peptide sellers. It is prohibited in sport under growth-hormone-releasing factors.
Many papers measure hormone concentrations over hours rather than patient-centered outcomes over months. Critical-illness and diagnostic studies do not establish benefits for healthy athletes.
Unapproved online peptides add risks that a paper about a verified laboratory compound cannot measure: mislabeling, contamination, sterility failure, degradation, and a concentration different from the label. Even an endogenous or short peptide can cause harm when the route, exposure, or manufacturing quality changes.
Frequently asked questions
What is GHRP-2?
GHRP-2, also called pralmorelin, is a synthetic growth hormone-releasing peptide that activates the ghrelin or growth-hormone secretagogue receptor. Researchers have used it to probe pituitary function and GH physiology. Online bodybuilding use is a separate, unapproved practice unsupported by robust clinical outcome trials.
How does GHRP-2 work?
GHRP-2 stimulates pulsatile growth hormone release through GHSR signaling and can work synergistically with growth-hormone-releasing hormone. The receptor also participates in appetite and metabolic signaling, so the peptide is not a selective muscle-growth switch. Acute hormone release does not by itself prove durable changes in body composition or performance.
Is GHRP-2 FDA-approved?
Not FDA-approved for bodybuilding or anti-aging. Approval is indication-specific and can differ by country; check current regulator labeling rather than relying on peptide-shop descriptions.
What does PubMed research on GHRP-2 show?
Human studies demonstrate neuroendocrine activity, including GH release in experimental and critical-illness settings. Reviews describe diagnostic and pharmacologic research, while anti-doping literature confirms misuse. There is no comparable randomized clinical program showing that self-administered GHRP-2 safely improves strength, recovery, or healthy aging.
What are the main risks of GHRP-2?
Potential effects include appetite changes, fluid retention, glucose disruption, and changes in cortisol or prolactin. Product purity is an additional risk when material comes from unregulated peptide sellers. It is prohibited in sport under growth-hormone-releasing factors.
PubMed sources
Every medical claim in this guide is anchored to peer-reviewed or scholarly literature indexed on PubMed. Open the abstracts below to review the study design, population, and limitations.
- Reactivation of pituitary hormone release and metabolic improvement by infusion of growth hormone-releasing peptide and thyrotropin-releasing hormone in patients with protracted critical illness. — PubMed 10199772 (1999)
- Neuroendocrinology of prolonged critical illness: effects of exogenous thyrotropin-releasing hormone and its combination with growth hormone secretagogues. — PubMed 9467533 (1998)
- Growth hormone-releasing peptides. — PubMed 9186261 (1997)
- Pralmorelin: GHRP 2, GPA 748, growth hormone-releasing peptide 2, KP-102 D, KP-102 LN, KP-102D, KP-102LN. — PubMed 15230633 (2004)
- Detection of GHRP-2 and GHRP-6 in urine samples from athletes. — PubMed 25809000 (2015)
Source selection and update method: PepMate Research Editorial Policy. Last updated 22 July 2026.